Analysts Issue Forecasts for Cybin FY2026 Earnings

Cybin Inc. (NYSE:CYBN) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Cybin in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($5.94) for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cybin’s current full-year earnings is ($4.76) per share.

A number of other equities analysts have also recently commented on the company. HC Wainwright dropped their target price on Cybin from $190.00 to $150.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Guggenheim assumed coverage on Cybin in a report on Thursday, March 13th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Canaccord Genuity Group dropped their price objective on Cybin from $86.00 to $73.00 and set a “buy” rating for the company in a report on Wednesday, February 12th.

Cybin Price Performance

NYSE:CYBN opened at $8.71 on Wednesday. The company has a market cap of $199.55 million, a price-to-earnings ratio of -1.99 and a beta of 0.68. The stock’s 50 day simple moving average is $7.05 and its two-hundred day simple moving average is $8.30. Cybin has a 1 year low of $4.81 and a 1 year high of $13.88.

Hedge Funds Weigh In On Cybin

Institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC purchased a new stake in shares of Cybin in the 4th quarter valued at approximately $46,000. Cowa LLC purchased a new stake in shares of Cybin in the 4th quarter valued at approximately $115,000. Essential Planning LLC. purchased a new position in shares of Cybin in the 4th quarter valued at $138,000. Fore Capital LLC grew its position in shares of Cybin by 70.6% in the 4th quarter. Fore Capital LLC now owns 31,421 shares of the company’s stock valued at $277,000 after buying an additional 13,000 shares during the last quarter. Finally, Diametric Capital LP acquired a new stake in Cybin during the 4th quarter worth $157,000. 17.94% of the stock is currently owned by institutional investors and hedge funds.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.